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Effects of Ibuprofen and Vicoprofen® 
on Physical Performance 
After Exercise-Induced Muscle Damage
Jaci L. VanHeest, Jim Stoppani, Tim P. Scheett, Valerie Collins, 
Melissa Roti, Jeffrey Anderson, George J. Allen, Jay Hoffman, 
William J. Kraemer, and Carl M. Maresh
Objective: To determine the effects of Vicoprofen® and ibuprofen on aerobic perfor-
mance, agility, and pain after exercise-induced muscle damage. Design: Double-blind 
randomized, placebo-controlled, repeated-dose clinical trial. Setting: Human-perfor-
mance and sports-medicine laboratory. Participants: 36 healthy men. Methods and 
Measures: Baseline testing was performed, 72 hours after which subjects performed 
eccentric exercise to induce muscle damage. They were evaluated for pain 24 hours 
postdamage and placed randomly into 3 groups: Vicoprofen (VIC), ibuprofen, or pla-
cebo (P). Postdamage testing was performed every day for 5 days. Subjects performed 
an economy run and a t-agility test to determine exercise performance. Results: The 
drugs had no significant effect on performance throughout the 5-day evaluation period. 
Pain was lower at days 4 and 5 in the VIC group than in P. Conclusions: It appears 
that Vicoprofen reduced pain after muscle damage, but the drug interventions did not 
enhance performance in aerobic and agility tasks. Key Words: agility, injury, medical 
therapy, running economy
VanHeest JL, Stoppani J, Scheett TP, et al. Effects of ibuprofen and Vicoprofen® on physical performance after ex-
ercise-induced muscle damage. J Sport Rehabil. 2002;11:224-234. © 2002 Human Kinetics Publishers, Inc.
Exercise-induced muscle damage can negatively affect muscle performance. 
It is characterized by a dull, aching pain that occurs after strenuous or un-
usual activity.1-4 The exercise-induced muscle damage results in soreness 
that typically increases during the 24 hours after exercise.4,5 The pain and 
stiffness peak 24–48 hours postexercise and return to baseline approximately 
5–7 days after the exercise bout. The symptoms can range from stiffness to 
debilitating pain that interferes with general movement activities.2,3,6-8
Various therapies have been employed in an attempt to diminish the 
discomfort associated with exercise-induced muscle damage, including 
topical ointments or thermal agents, ultrasound, and anti-inflammatory 
agents.6,7 Ibuprofen is a typical anti-inflammatory drug used to relieve 
The authors are with the Human Performance Laboratory, Dept of Kinesiology, Uni-
versity of Connecticut, Storrs, CT 06269.
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muscle pain and soreness. It reduces the production of prostaglandins and 
oxygen radicals but does not affect the loss of calcium after the injury.7 The 
doses of ibuprofen associated with these effects, however, are greater than 
those used in the present study.
Although anti-inflammatory medications can provide pain relief in 
exercise-induced muscle damage, a combination treatment of opiate and 
anti-inflammatory agent might be more beneficial.9 The analgesic effect of 
ibuprofen is augmented in this preparation, resulting in decreased pain 
throughout the recovery process. One preparation containing 7.5 mg hydro-
codone bitartrate and 200 mg ibuprofen (Vicoprofen®) is similar to drugs 
used successfully in other clinical conditions. The beneficial effects of the 
combination drug could enhance both pain masking and muscle healing. 
Therefore, the purpose of our study was to examine the effects of 2 drug 
interventions (ibuprofen and Vicoprofen) on performance on physical work 




Thirty-six moderately fit men, age 18–34 years, were recruited for the study. 
Table 1 shows the physical characteristics of the subjects. Each subject was 
randomly assigned to 1 of 3 experimental groups (n = 12/group; IBU = 
ibuprofen, VIC = Vicoprofen, P = placebo). The study protocol was ap-
proved by the University of Connecticut’s Committee for the Protection of 
Human Subjects, and each subject gave informed consent before initiating 
the study protocol. Medical history, activity questionnaires, and physician 
clearance were completed before entry into the study. Each subject com-
pleted a 3-day food diary. Subjects who consumed more than 30% of their 
calories from protein were excluded from the study. The subjects were not 
athletes, nor had they been regular participants in organized competitive 
Table 1 Physical Characteristics of Study Subjects*
                         Age                     Height               Body mass              Body fat 
                          (y)                      (cm)                      (kg)                       (%)
VIC                 20 ± 0              173.6 ± 3.0           71.8 ± 2.1             14.8 ± 1.3
IBU                 19 ± 0              164.5 ± 1.8           69.3 ± 2.4             16.6 ± 1.9
P                     20 ± 0              178.4 ± 3.0           78.7 ± 3.9             17.6 ± 1.8
*Mean ± SEM. VIC indicates Vicoprofen®; IBU, ibuprofen; and P, placebo.
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athletics for a period of at least 6 months before the study. They were al-
lowed to participate in recreational activities such as swimming, jogging, 
or other aerobic activities, but they could not have participated in lower 
body resistance training during the preceding year.
Study Design and Muscle-Damage Protocol
The study design was a double-blind randomized, placebo-controlled, 
repeated-dose trial. All subjects completed a series of initial assessments 
including maximal oxygen consumption, body composition, and history 
and physical screening. These assessments were used both as screening 
evaluations and as descriptive data regarding the subject group. After the 
screening evaluations (day V3), each subject completed a series of baseline 
tests (including each of the dependent variables: running economy, t-agility 
performance, pain scores, and creatine kinase [CK]; Figure 1). The baseline 
testing allowed the subjects to familiarize themselves with the testing pro-
tocols and served to reduce the potential confounding learning or training 
effects associated with test performance.
The following day (V4), each subject performed an eccentric-exercise 
protocol to induce muscle damage. The protocol consisted of seated knee 
flexion, starting with a straight leg, followed by flexion of the knee. The con-
tractions were performed on an isotonic leg-extension machine that allowed 
for the resistance to remain constant while the speed of the contraction could 
change. The protocol was completed with single-leg contractions using the 
dominant leg. Approximately 100 contractions were performed against a 
resistance of 120% of the 1-repetition-maximum concentric load.10
Twenty-four hours after the damage protocol (V5), the subjects were 
evaluated for pain after a single-leg (damaged leg), unweighted squat us-
ing a visual analog scale (VAS). Subjects with mild or greater pain levels 
were randomized into 1 of the 3 experimental groups (VIC, IBU, or P). 
Treatment was administered (as per protocol in following section) for the 
Figure 1 Study design timeline including visits to the laboratory (V), performance 
and cognitive testing (Perf), blood draws (BL) and corresponding hours before or after 
the eccentric-exercise damage protocol. The administration of study medications is 
also included (MEDS).
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subsequent 4 days (V6–V9). All dependent variables were measured under 
similar conditions (ie, time of day, room temperature, and test order) for 
each of the remaining days of the protocol (V6–V9).
Drug Administration
All subjects were required to take their medication 4 times per day (every 
4–6 hours). The IBU group took one 200-mg tablet per dose, which allowed 
for comparison with the ibuprofen content in the VIC dosage. The VIC group 
consumed tablets containing 7.5 mg hydrocodone bitartrate with 200 mg 
ibuprofen (Vicoprofen, Knoll Pharmaceutical Co, Mt. Olive, NJ). The P group 
was given a placebo medication. Dosing began after testing on day 5 of the 
protocol (24 hours after damage) and was administered in the presence of 
a member of the research team. The remaining 3 doses of the drug were 
taken over the following day, the final dose immediately before the testing 
session on day 6. From day 6 forward (through day 9), the subjects would 
receive a bottle containing 4 pills, 1 of which was taken in the presence of 
a study investigator, and the final pill was taken just before the subsequent 
day’s testing session. The subjects were not allowed to take any additional 
medications during the study period.
Aerobic Performance
The running-economy profile was performed in 4 continuous stages on a 
motorized treadmill at 0% incline. Five-minute stages began at 2.5 mph, 
followed by additional stages at 5, 6, and 7 mph. Oxygen consumption 
(VO2) and respiratory-exchange ratio were measured for the final 3 minutes 
of each running speed. During the last minute of each stage, the subjects 
selected a rating of perceived exertion (RPE) according to the Borg scale.11 
RPE was determined for each leg and for the total body. Heart rate was 
recorded during the last minute of each stage by a heart-rate monitor. The 
protocol was designed to assess running economy in such a manner that 
moderately fit individuals could perform the task.
t-Agility Test
The t-agility test was used to determine the agility of the subjects before 
and after the damage protocol. The subjects sprinted in a straight line from 
a standing start to a cone 9 m away, followed by a side-shuffle left (without 
crossing the feet) to a cone 4.5 m away. After touching the cone, the subjects 
side-shuffled right to a cone placed 9 m away and then side-shuffled back 
to the middle cone. A final backpedal motion to the starting line completed 
the test. Each subject performed 2 trials of the test, with the fastest time 
recorded.
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Pain Assessment
A VAS was used to determine subjects’ pain. Pain was assessed after a 
single-leg (damaged leg), unsupported, unweighted squat. The VAS was a 
10-cm linear scale with labels no pain and pain as bad as can be on either end. 
Each subject would subjectively mark his pain rating on the scale, and the 
distance (cm) from the no pain point was measured as the raw pain score. 
A daily pain score was recorded after the single-leg (damaged leg) squat 
performance, and this value served as a baseline pain measure each day 
of the protocol.
Blood Collection and Creatine-Kinase Analysis
Blood was collected daily (V5–V9; see Figure 1) via venipuncture from 
an antecubital vein. Blood was centrifuged and the serum placed into 
aliquots and stored at –85°C for later analysis. CK concentrations were 
determined in duplicate using a colorimetric assay (Sigma Chemical Co, 
St. Louis, Mo). Intra-assay and interassay variances were less then 5% and 
10%, respectively.
Data Analysis
Analysis of variance (ANOVA) with repeated measures was used to sta-
tistically evaluate the data set. When appropriate, Fisher least-significant-
difference post hoc tests were used for pairwise comparisons. Statistical 
significance was chosen as P≤ .05.
Results
Data were analyzed for the period of time that both passive recovery and 
medications were employed (48–120 hours postdamage). This time period 
was used because it resembles the care that many athletes experience after 
muscle damage.
Serum CK was significantly elevated in all groups after the muscle-dam-
age protocol. Comparisons between the groups indicated that there were 
no significant differences at any time point measured. The CK values were 
similar to data reported previously using the same damage protocol.12
Figure 2 illustrates the response in oxygen consumption to running at the 
6-mph stage in the 3 experimental groups over time. VO2 was significantly 
greater in the VIC group than in IBU at 24 hours postdamage. All other 
comparisons were not significantly different between the groups in oxygen 
consumption. For heart rate (Figure 3), the P group was significantly higher 
(179 ± 3 beats/min) than both VIC (169 ± 5 beats/min) and IBU (167 ± 4 
beats/min) at 24 hours postdamage. Heart rate also was not significantly 
different between groups at any of the remaining time points measured in 
this study.
228 VanHeest et al Vicoprofen® and Physical Performance 229
RPE varied slightly during the aerobic-performance (running economy) 
test for each group and was not shown to be different between groups 
throughout the recovery period. RPE data for each group in the dominant 
(injured) and nondominant (uninjured) legs were also not different be-
tween groups, but there was a trend for the injured leg (dominant) to have 
somewhat higher RPE values in both the P and IBU groups at 24 (P = 14 ± 
1, VIC = 12 ± 1, IBU = 14 ± 1) and 48 (P = 13 ± 1, VIC = 12 ± 1, IBU= 13 ± 1) 
hours after the damage protocol.
Pain-rating data are presented in Table 2. There were no significant dif-
ferences between groups in VAS after the unloaded single-leg squat. VAS 
scores were significantly lower in the VIC group at 48 and 72 hours than in 
P after both the aerobic-performance test and the t-agility test. There were 
no differences reported at any other time point measured.
Figure 2 Oxygen-uptake response at 24, 48, 72, 96 and 120 hours after muscle-
damage protocol for the 3 experimental groups. Values are mean ± SEM. 
*vs P (P ≤ .05).
Figure 3 Heart-rate response at 24, 48, 72, 96 and 120 hours after muscle-damage 
protocol for the 3 experimental groups. Values are mean ± SEM. 
*vs P (P ≤ .05).
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Figure 4 depicts the t-agility test results. Although the P group’s times 
appeared to be somewhat slower than those of either VIC or IBU throughout 
the entire recovery period, there were no significant differences between 
groups at any point in the recovery process. The findings were driven by 
the large variability in the P-group data at each time point measured.
Discussion
The present study was designed to test the effect of 2 drug interventions on 
measures of physical performance after exercise-induced muscle damage. 
We hypothesized that the VIC condition would provide significant percep-
tual alterations during the recovery period and that the benefits would be 
seen in more rapid return to baseline.
Eccentric exercise causes substantial muscle damage2,13 that can be mea-
sured, indirectly, by evaluating CK in the blood.10,14,15 In the present study, CK 
was significantly increased in all groups after the muscle-damage protocol. 
The drug interventions did not appear to have a significant effect on the 
delayed onset of muscle soreness or the CK values over the 5-day recovery 
Table 2 Pain Assessments During Aerobic-Exercise Bout (6 mph), 
t-Agility Test, and Squat Using a Visual Analog Scale (VAS) After an 
Eccentric Muscle-Damage Protocol*
                                                           Time Postdamage
                         24 h                48 h               72 h               96 h              120 h
Squat VAS
   VIC          4.23 ± 0.59    3.08 ± 0.70   2.00 ± 0.40   1.78 ± 0.34    0.83 ± 0.28
   IBU         4.42 ± 0.69    2.97 ± 0.46   2.06 ± 0.51   1.22 ± 0.25    1.40 ± 0.83
   P              5.05 ± 0.68    4.25 ± 0.63   3.01 ± 0.59   1.94 ± 0.49    1.28 ± 0.49
Aerobic VAS                                
   VIC          5.23 ± 0.51    3.23 ± 0.50† 2.80 ± 0.44†  2.48 ± 0.51    1.90 ± 0.69
   IBU         6.10 ± 0.68    4.08 ± 0.70   3.64 ± 0.76   2.35 ± 0.73    1.55 ± 0.54
   P              5.87 ± 0.79    5.75 ± 0.81   4.40 ± 0.76   2.70 ± 0.67    2.26 ± 0.78
t-Agility VAS                                
   VIC          4.68 ± 0.61    3.02 ± 0.68† 2.37 ± 0.45†  1.99 ± 0.46    1.35 ± 0.53
   IBU         5.51 ± 0.53    3.58 ± 0.48   2.62 ± 0.60   1.55 ± 0.26    0.98 ± 0.23
   P              6.14 ± 0.78    5.13 ± 0.85   3.92 ± 0.79   2.33 ± 0.59    1.90 ± 0.72
*Mean ± SEM. VIC indicates Vicoprofen®; IBU, ibuprofen; and P, placebo.
†vs P.
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period. The CK values indicated that muscle damage was present in these 
subjects (24 hours after the damage protocol).
The study protocol resulted in a pattern of elevated CK values in the VIC 
group, in which they were significantly elevated over predamage values at 
days 3 through 5. It is probable that the subjects in the VIC group did not 
feel the level of discomfort associated with the treadmill running and agil-
ity testing because of a more effective pain medication including an opiate. 
Therefore, they might have run somewhat more aggressively, resulting in 
additional damage. The damage could have been increased because of the 
nature of the running protocol (ie, relatively greater eccentric component) 
in all groups tested; therefore, the CK values remained elevated through-
out the protocol. A similar phenomenon has been reported in marathon 
runners.16 The potential pain masking in the VIC group could be a risk for 
injured athletes, who could further injure their muscles while recovering 
from an initial muscle injury.
Muscle damage should cause a decrease in the person’s ability to perform 
steady-state aerobic work (a decrease in economy and efficiency). As the 
individual begins to heal, he or she should return to baseline values. Any 
pharmacological agent that facilitates healing or masks pain or discomfort 
could positively affect running economy. Furthermore, if the drug inter-
vention reduced the perception of pain or discomfort, the subject should 
report lower perceived exertion than would individuals not receiving the 
treatment.
The 2 measures used in this study to evaluate steady-state running per-
formance were oxygen uptake and heart rate. Each group remained fairly 
constant in VO2 during the 6-mph stage of the test throughout the study. 
HR was reduced, however, in the VIC group at its highest value (24 hours 
postdamage) throughout the protocol (Figure 3), and it returned more 
Figure 4 t-Agility response at 24, 48, 72, 96 and 120 hours after muscle-damage 
protocol for the 3 experimental groups. Values are mean ± SEM.
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rapidly to baseline than in the other 2 treatment groups. The medication 
taken by the VIC group has been shown to produce centrally mediated 
effects.7,9,17 Potential influence of the VIC drug on central-nervous-system-
mediated autonomic control of heart rate might have been evident in these 
subjects throughout the study. Further exploration of these phenomena is 
warranted.7,9,17
The impact of the drug interventions on the perception of physical 
exertion both globally and in each leg separately followed many of the 
trends hypothesized. Total-body RPE was initially elevated after the dam-
age protocol (24 hours) and gradually returned to baseline in all 3 groups. 
The VIC group, as expected, showed the smallest increase in RPE values 
after the damage protocol, followed by the IBU group. It is clear that the 
pain- or discomfort-masking properties of these agents were evident in 
this group of subjects.
Dominant-leg RPE response (the damaged leg) was similar to the global 
RPE response, with the VIC and IBU groups reduced in response over time. 
These findings support the work of Hasson et al,7 who examined the in-
fluence of ibuprofen on muscle soreness. Perception of muscle soreness after 
a therapeutic dose of ibuprofen (24-hour TID) was significantly diminished 
compared with placebo 48 hours after exercise. Nondominant-leg findings 
were consistent with the a priori hypothesis of no change throughout the 
protocol.
Agility during the muscle-damage period should be reduced because 
of the physical damage to skeletal-muscle fibers. Although there might be 
functional motor units throughout the muscle, motor units should be dam-
aged after the eccentric-exercise protocol in specific regions of the muscle. It 
is possible that the drug interventions reduce the perception of pain or dis-
comfort, thereby allowing the subjects to return to baseline agility measures 
more readily. Results from the present study do not support this hypothesis. 
All 3 experimental groups improved in agility from the baseline measure. 
In addition, the P group was slower than either the IBU or the VIC group 
during every visit (including baseline). IBU subjects returned to baseline 
values more rapidly than either the P or the VIC group. This suggests that 
the effects of IBU on the cellular reconstruction of skeletal muscle during 
recovery might influence an individual’s ability to perform rapid physical 
tasks requiring coordinated movements.
It appears that the pain data do not directly relate to either of the per-
formance tests. Pain was reduced at 48 and 72 hours in the VIC group after 
both the economy run and the agility test, but it was not accompanied by 
a significant improvement in performance. Coupled with the elevated CK 
data in this group, however, it could be speculated that the masked pain 
might result in increased damage with these types of running activities. It 
could be postulated that these tests are not limited by the single-leg damage 
that each subject endured. Performance of running economy is influenced by 
multiple factors, many of which are central (ie, cardiorespiratory function). 
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The single-leg damage would only account for a small additional demand 
placed on these subjects. Similarly, the t-agility test evaluated the subjects’ 
neuromuscular ability and coordination. The impact of the single-leg dam-
age might not have been a large enough stimulus to significantly disrupt 
overall performance on this test.
The present study is the first to examine the influence of Vicoprofen treat-
ment on the recovery of running economy and agility tasks similar to those 
required in many sport activities. Recreational and competitive athletes are 
often plagued with soft-tissue injuries that include muscle damage. Sports-
medicine physicians often prescribe pharmacological agents to decrease 
both inflammation and pain from these injuries. It appears that combination 
medications (ie, opiate and ibuprofen) can be effective in reducing pain and 
discomfort after exercise-induced muscle damage. Furthermore, the impact 
of ibuprofen alone on perception of pain was similar to the combination 
treatment, although not as significant in magnitude. The influence of these 
agents on recovery in terms of physical performance on either aerobic or 
agility tasks remains unremarkable. Athletes who experience muscle pain 
caused by training damage might benefit perceptually from the medications 
evaluated in this study, but the influence of these drugs on the inflamma-
tory and healing processes remains unclear. Further research is necessary to 
determine the influence of these drug interventions on the factors involved 
in the muscle-healing and -regeneration processes.
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